Posted by Michael Wonder on 06 Nov 2021
Tris Pharma announces FDA approval of Dyanavel XR (amphetamine) once daily extended release oral tablets, CII, for ADHD
5 November 2021 - In a clinical study in adults, Dyanavel XR tablets demonstrated bioequivalence to Dynavel XR (amphetamine) extended-release oral suspension.
Tris Pharma announced today that the U.S. FDA has approved Dyanavel XR (amphetamine), extended release once-daily tablets, CII, for the treatment of attention-deficit hyperactivity disorder in patients 6 years and older.
